|  | 


India Accelerates Review of Pfizer and Astra Covid-19 Vaccines: Official


India is accelerating its review of coronavirus vaccines developed by Pfizer Inc and AstraZeneca for emergency use, a senior government official said on Monday, as the world’s second-worst-hit country struggles to contain the outbreak.

The Indian government is pinning its hopes of mass supply of the vaccine to the Serum Institute of India, the world’s largest vaccine producer by volume, which submitted the first formal application for emergency use approval for the Covid-19 vaccine on Monday. for AstraZeneca Plc.

Read also | Explanation of the emergency use authorization for Covid-19 vaccines

Pfizer Inc had already applied for emergency use approval for its vaccine in India over the weekend, said the official, who did not want to be named.

“We are in the review process. It is an accelerated review process, which is also there for Serum, ”said the government official.

“It is the need of the moment. We have to review as soon as possible. “

Click here for full Covid-19 coverage

The second most populous country in the world with more than 1.3 billion people has 9.68 million infections, while more than 140,000 people have died from Covid-19. The lockdowns imposed to contain the spread of the virus have plunged the economy into one of its worst recessions in decades.

Serum Institute CEO Adar Poonawalla tweeted that the decision to request emergency use “will save countless lives,” but did not elaborate.

The company declined to respond to follow-up questions from Reuters about the process.

AstraZeneca, Pfizer, and Moderna Inc are among drug makers seeking advanced approvals for their vaccines, which governments increasingly see as the only way to stop a pandemic that will soon complete a year since it was first reported in China. .

Read also | UK to Brexit-Proof Pfizer Covid-19 Vaccine Supplies from Belgium

AstraZeneca’s vaccine, named “Covishield” by the Serum Institute, has less stringent storage requirements and is expected to be easier to distribute and faster to scale up in low-income countries.

But he also faces inquiries from scientists about his trial data, which showed that a 1.5-dose regimen delivered more than 90% efficacy and a full two-dose regimen only 62%, both administered in two stages.

Britain and some other nations have gone ahead with their plans to roll out the AstraZeneca vaccine, while the Philippines and Thailand secured millions of doses, giving the injection a vote of confidence after experts raised questions about the data from the test.

AstraZeneca said two weeks ago that it could launch an additional trial to evaluate the lower dose regimen, but the Serum Institute has said that it will continue to test only the two full doses as it would delay testing.

Poonawalla has said https://www.reuters.com/article/us-health-coronavirus-india-vaccine-idUKKBN28321S that the company will first focus on supplying the vaccine in India before distributing it to other countries, priced at 1,000 rupees per dose ($ 13.50) for private markets.

The Serum Institute has also said that an emergency use approval could precede a full rollout in February or March.

View original